Addressing Clinical Challenges in the Long-Term Treatment of Schizophrenia
neuroscienceCME Podcast
Premiere Date: Friday, February 22, 2008This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
Credit Expiration Date:
Sunday, February 22, 2009
 | Charles B. Nemeroff, MD, PhD Professor and Chairman Department of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
 | Peter F. Buckley, MD Professor and Chairman Department of Psychiatry and Health Behavior Associate Dean for Leadership Development Medical College of Georgia Augusta, GA |
 | Stephen R. Marder, MD Director of VISN 22 Mental Illness Research Education Clinical Center Dept. of Veterans Affairs Director of the Section on Psychosis Semel Institute at UCLA Los Angeles, CA |
 | John W. Newcomer, MD Gregory B. Couch Professor of Psychiatry, Psychology and Medicine Director, Clinical Trials Unit, Institute of Clinical and Translational Sciences (ICTS) Director, Regulatory Support Center, ICTS Medical Director, Center for Clinical Studies Washington University School of Medicine St. Louis, MO |
Schizophrenia is a chronic debilitating condition affecting 2.2 million individuals in the United
States and 51 million people worldwide.(1) Expert panels recently have defined and operationalized
remission and recovery as treatment targets.(2) A number of considerations, including the
pharmacology of the particular agent, its efficacy, safety, and tolerability, all must be balanced in
selecting a long-term treatment plan. Particular attention must be paid to iatrogenic effects of
the atypicals on cardiometabolic risk factors, and psychiatrists need to integrate screening and
monitoring for such risks into their practice.(3) Switching medications may be a necessity in patients
with metabolic or other unwanted side effects from atypical antipsychotics, and it is important
to understand when and how to switch medications.(4) In this podcast series, experts will discuss
remission and recovery as treatment goals, identification and management of metabolic concerns,
and indications and methods for switching antipsychotics.
Module 1: Defining and Assessing Remission and Recovery
Module 2: Identifying and Managing the Iatrogenic Effects of Antipsychotic Medications on
Weight Gain and Other Metabolic Parameters
Module 3: Indications and Methods for Switching Antipsychotic Medications
- http://www.nih.gov
- Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449.
- Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl 4):8-13.
- Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" mediations. J Clin Psychiatry 2007;68(suppl 6):14-23.
To apply concepts related to the long-term management of patients with schizophrenia and specifically in the areas of remission and recovery, metabolic consequences of atypical antipsychotics, and switching.
At the end of this CE activity, participants should be able to:
- Define and operationalize remission and recovery.
- Apply data on weight gain in patients with schizophrenia to the development of an effective screening and monitoring plan.
- Discuss clinical considerations involved in switching atypical antipsychotic medication.
Physicians, physician assistants, nurses, nurse practitioners, psychologists, social workers, certified case managers, pharmacists, and other clinicians that participate in the long-term management of patients with schizophrenia.
CME Outfitters, LLC, gratefully acknowledges an educational grant from Wyeth Pharmaceuticals and Solvay Pharmaceuticals in support of this CE activity.
CME Credit (Physicians):
CME Outfitters, LLC, is
accredited by the Accreditation Council
for Continuing Medical Education to
provide continuing medical education
for physicians.
CME Outfitters, LLC, designates this educational activity
for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved
provider of continuing nursing education by the New
York State Nurses Association, an accredited approver by
the American Nurses Credentialing Center’s Commission
on Accreditation.
It has been assigned code 6WASUP-PRV-0632. 1.0
contact hours will be awarded upon successful
completion.
Note to Nurse Practitioners: The content of this CNE
activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved
by the American Psychological Association to sponsor
continuing education for psychologists. CME Outfitters
maintains responsibility for this program and its
content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was
approved by the National Association of Social Workers
(provider #886407722) for 1.0 continuing education
contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-000-08-008-H01-P
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).
Charles B. Nemeroff, MD, PhD, Moderator
Dr. Nemeroff was born in New York City in 1949 and educated in the New York City Public School System. After graduating from the City College of New York in 1970, he enrolled in graduate school at Northeastern University and received a Master's degree in Biology in 1973. He received his MD and PhD (Neurobiology) from the University of North Carolina at Chapel Hill. His residency training in psychiatry was conducted at both the University of North Carolina and at Duke University, after which he joined the faculty of Duke University. At Duke he was Professor of Psychiatry and Pharmacology and Chief of the Division of Biological Psychiatry before relocating in 1991 to Emory University School of Medicine in Atlanta, Georgia, where he is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences. His research has concentrated on the biological basis of the major neuropsychiatric disorders, including affective disorders, schizophrenia, and anxiety disorders. His clinical research is focused on the use of genetic, neuroendocrine, neuroimaging and neurochemical methods to comprehensively understand the pathophysiology of depression. In recent years he has uncovered the neurobiological mechanisms that mediate the increased risk for depression in victims of child abuse. He has also contributed to other seminal findings such as the burgeoning area of research concerning the relationship of depression to cardiovascular disease, as well as to identifying predictors of specific antidepressant treatment responses.
Dr. Nemeroff has received numerous honors during his career, including the A.E. Bennett Award from the Society of Biological Psychiatry (1979), the Judith Silver Memorial Young Scientist Award from the National Alliance for the Mentally Ill (1989), both the Kempf Award in Psychobiology (1989) and the Samuel Hibbs Award (1990) from the American Psychiatric Association (APA), and the Gold Medal Award and the Research Prize (1996) from the Society of Biological Psychiatry. In 1993 he was awarded the Edward J. Sachar Award from Columbia University and the Edward A. Strecker Award from The Institute of Pennsylvania Hospital. In 1997, he was the recipient of the Gerald Klerman Award from the National Depressive and Manic-Depressive Disorders Association and the Selo Prize from the National Alliance for Research in Schizophrenia and Depression. In 1998 he was the recipient of the Research Award in Mood Disorders from the American College of Psychiatrists and in 1999 he received the Bowis Award from the same organization. He was awarded the Menninger Prize in 2000 from the American College of Physicians, the Research Award from the American Foundation for Suicide Prevention in 2001, and the Burlingame Prize from the Institute of Living in 2002. In 2006 he received the American Psychiatric Association Research Mentoring Award and Vestermark Award. Dr. Nemeroff served as the Editor-in-Chief of Neuropsychopharmacology (2001-2006). With Alan F. Schatzberg, MD, he is co-Editor of the Textbook of Psychopharmacology, soon to be in its Fourth Edition, published by the American Psychiatric Association Press. He has served on the Mental Health Advisory Council of the National Institutes of Mental Health and the Biomedical Research Council for NASA. He is past President of the American College of Neuropsychopharmacology and the American College of Psychiatrists. He is currently a member of the Board of Directors of the American Foundation for Suicide Prevention and President of its Scientific Council. He is chair of the APA Committee on Research Training. In 2002 he was elected as a member of the Institute of Medicine of the National Academy of Sciences.
He is currently the recipient of several research grants from the NIH, including a Conte Center for the Neurobiology of Major Mental Disorders, and has published more than 850 research reports and reviews.
Peter Buckley, MD
Peter F. Buckley, MD, is Professor and Chairman in the Department of Psychiatry and Associate Dean for Leadership Development at the Medical College of Georgia in Augusta.
Dr. Buckley immigrated to America in 1992 after completing his medical degree and postdoctoral training at the University College Dublin School of Medicine in Ireland. His thesis was on the subject of neuroimaging and neurodevelopment in schizophrenia. Before joining the Department of Psychiatry at the Medical College of Georgia, Dr. Buckley was Professor of Psychiatry and Vice Chair in the Department of Psychiatry at Case Western Reserve University School of Medicine in Cleveland, Ohio and served as Medical Director at Northcoast Behavioral Healthcare System (NBHS), the adult state psychiatric services for Cleveland and Toledo, Ohio.
Dr. Buckley conducts research on the neurobiology and treatment of schizophrenia. He is author of a textbook on psychiatry and has edited seven specialist books on schizophrenia, as well as publishing widely in major psychiatric journals with over 250 book chapters, articles, and abstracts. Buckley is also Editor-in-Chief of Clinical Schizophrenia & Related Psychoses and the Journal of Dual Diagnosis. Dr. Buckley is on the editorial board of six other journals. Dr. Buckley has been a contributor to several expert consensus guidelines and is a federally funded investigator in the treatment of schizophrenia. Dr. Buckley is chair of the schizophrenia spectrum disorders and late life review committee of the National Institute of Mental Health. Dr. Buckley is on the board of several professional organizations, is a member of the Scientific Board of the National Alliance for the Mentally Ill, is subcommittee member of a gubernatorial task force for mental health in Georgia, and he is listed in Best Doctors in America. He is the recipient of several awards for his work, including an Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill and the 2006 Georgia Psychiatrist of the Year Award. Dr. Buckley is also the recipient of the American Psychiatric Association Administrative Psychiatric Award for his work on State-University Collaborations.
Stephen R. Marder, MD
Dr. Marder received his AB from the University of Pennsylvania and his MD from the State University of New York at Buffalo. After an internship at Denver General Hospital, he completed a residency at the University of Southern California. From 1975 to 1977 he was a Clinical Associate in the Biological Psychiatry Branch at the National Institute of Mental Health. In 1977 he joined the staff at the Brentwood VA Medical Center and the faculty at UCLA.
Dr. Marder's research has focused on the drug treatment of schizophrenia and the pharmacology of antipsychotic drugs. He has authored or co-authored more than 200 journal articles and chapters based on research. He is currently the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs and the Director of the Section on Psychosis at the UCLA Semel Institute for Neuroscience and Human Behavior. He is the leader of the NIMH MATRICS program for facilitating the development of drugs for improving neurocognition in schizophrenia and the Principal Investigator of the NIMH Treatment Units for Research on Neurocognition in Schizophrenia.
Dr. Marder has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Stanley Dean Research Award of the American College of Psychiatry, the Alexander Gralnick Award from the American Psychiatric Association, and the Kempf Award from the American Psychiatric Association. He is listed in The Best Doctors in America and America's Top Doctors.
John W. Newcomer, MD
John W. Newcomer, MD, is the Professor of Psychiatry, Psychology, and Medicine at Washington University School of Medicine in St. Louis. He is also the Medical Director for the Center for Clinical Studies at Washington University. Dr. Newcomer is a Principal Investigator on research grants funded through the National Institutes of Health (NIH), and also serves as the Chairman of the Drug Utilization Review (Medicaid) Board for the State of Missouri.
Dr. Newcomer has received a number of honors and awards, including a 1999 Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (NAMI), an Independent Scientist Award from the National Institute of Mental Health (NIMH), and a 2002 Gerald L. Klerman Award for Outstanding Clinical Research from the National Alliance for Research on Schizophrenia and Depression (NARSAD). Funded continuously by the NIH for 15 years, Dr. Newcomer has also served as a reviewer for the NIH as well as other funding agencies, including the Department of Veteran's Affairs and the National Science Foundation.
Dr. Newcomer serves on the editorial board for Neuropsychopharmacology, Journal of Clinical Psychiatry, Journal of Psychotic Disorders and Obesity, and he is a reviewer for numerous journals, including the New England Journal of Medicine, Diabetes Care, American Journal of Physiology, American Journal of Psychiatry, Archives of General Psychiatry, and the Journal of Neuroscience. He has contributed numerous articles to leading scientific journals, including Archives of General Psychiatry, The Journal of Clinical Endocrinology & Metabolism, The Journal of Neuroscience, The Journal of the American Medical Association, and Neuropsychopharmacology.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff consulted to, served on the Speakers' Bureau and/or Board of Directors, has been a grant recipient, and/or owned equity in one or more of the following: Abbott Laboratories, Acadia Pharmaceuticals, American Foundation for Suicide Prevention( AFSP), American Psychiatric Institute for Research and Educations(APIRE), AstraZeneca Pharmaceuticals, BMC-JR LLC, Bristol-Myers Squibb Company, CeNeRx, Corcept Therapeutics, Cypress Bioscience, Inc., Cyberonics, Inc., Eli Lilly and Company, Entrepreneur's Fund, Forest Laboratories, Inc., George West Mental Health Foundation, GlaxoSmithKline, H. Lundbeck A/X, i3 DLN, Janssen LP, National Alliance for Research on Schizophrenia and Depression( NARSAD), National Institute on Mental Health, Neuronetics Inc., NFMH, NovaDel Pharma Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Quintiles Transnational Corp., Reevax, UCB Pharma, Wyeth-Ayerst. Currently, Dr. Nemeroff serves on the Scientific Advisory Board for AstraZeneca Pharmaceuticals, Johnson & Johnson, Pharma Neuroboost, Forest Laboratories, Inc., National Alliance for Research on Schizophrenia and Depression, and Quintiles Transnational Corp. He is a grant recipient from the American Foundation for Suicide Prevention, National Alliance for Research on Schizophrenia and Depression, and the National Institute of Health. He serves on the Board of Directors of American Foundation for Suicide Prevention, APIRE, NovaDel Pharma, Inc., Mt. Cook Pharma, Inc., and the George West Mental Health Foundation. He owns equity in CeNeRx and Reevax. He owns stock or stock options in Corcept Therapeutics, Inc. and NovaDel Pharma, Inc.
Dr. Buckley has disclosed that he receives grant/research support from AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Janssen Pharmaceutica, National Institute of Mental Health, Pfizer Inc., Solvay Pharmaceuticals, and Wyeth Pharmaceuticals. He serves as a consultant to Abbott Laboratories, Alamo Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Janssen Pharmaceutica, Pfizer Inc., Merck, Roche Diagnostics, Solvay Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Buckley receives honoraria from Abbott Laboratories, Alamo Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Janssen Pharmaceutica, and Pfizer Inc.
Dr. Marder has disclosed that he receives grants/research support from Merck & Co., Inc., and Allon Therapeutics. He serves as a consultant to Bristol-Myers Squibb Company, GlaxoSmithKline, Hoffmann La-Roche, Memory Pharmaceuticals, Otsuka America Pharmaceuticals, Pfizer Inc., Solvay Pharmaceuticals, and Wyeth Pharmaceuticals.
Dr. Newcomer has disclosed that he receives grants/research support from Bristol-Myers Squibb Company, Janssen, Pfizer Inc., The National Institute of Mental Health, The National Alliance for Research on Schizophrenia and Depression, Sydney R. Baer Jr. Foundation, and Wyeth Pharmaceuticals. He serves as a consultant to AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen, Pfizer Inc., Organon, Solvay Pharmaceuticals, and Wyeth Pharmaceuticals. Dr. Newcomer has received royalties from Compact Clinicals.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Wyeth Pharmaceuticals, and Solvay Pharmaceuticals do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
PC-004-022208-14
